Cannabigerol draws interest, but veterinary evidence is still thin
Bottom line
Veterinary Practice News this week put a spotlight on cannabigerol, or CBG, a lesser-known cannabis-derived cannabinoid that’s starting to show up in conversations with pet parents and in veterinary integrative medicine circles. The article argues that CBG is drawing interest because early research suggests anti-inflammatory potential, possible topical benefits for skin disease, and a different pharmacologic profile from cannabidiol, or CBD. But the evidence base in veterinary species is still thin: a 2022 dog pharmacokinetic and safety study found short-term oral CBG/CBGA dosing was well tolerated in a small group of healthy dogs, and a 2024 comparative review said that remains one of the only published canine datasets specific to CBG. (veterinarypracticenews.com)
Why it matters: For veterinary professionals, CBG is the next cannabinoid likely to generate client questions before clinical guidance catches up. The key practical issue is that enthusiasm is outpacing species-specific evidence, especially on efficacy, dosing, long-term safety, drug interactions, and product quality. FDA has not approved cannabis for treatment of any disease or condition in animals, and the agency has said products intended to affect the structure or function of the body of humans or animals are regulated as drugs. FDA also sought public comment in 2025 on veterinarians’ experiences with cannabis-derived products in animals, underscoring that the regulatory and safety picture is still evolving. (fda.gov)
What to watch: Expect more scrutiny of veterinary cannabis products, and watch for additional canine and feline studies that move CBG from mechanistic promise to clinically useful evidence. (fda.gov)
Key facts
- Compound
- Cannabigerol, or CBG
- Context
- A cannabis-derived cannabinoid drawing interest in veterinary integrative medicine
- Potential uses
- Anti-inflammatory effects, topical use for skin disease, and possible gastrointestinal interest
- Evidence gap
- Veterinary evidence is still limited, especially for efficacy, dosing, long-term safety, drug interactions, and product quality
- Canine study
- A 2022 dog pharmacokinetic and safety study found short-term oral CBG/CBGA dosing was well tolerated in healthy dogs
- Comparative review
- A 2024 review said only one published paper had specifically evaluated physiological effects of CBG and CBGA in dogs
- FDA position
- FDA has not approved cannabis for treatment of any disease or condition in animals
- FDA regulation
- FDA says products intended to affect the structure or function of the body are regulated as drugs
- FDA action
- In January 2025, FDA sought public comment on veterinarians’ experiences with cannabis-derived products in animals
Cannabigerol, or CBG, is emerging as the next cannabis-derived compound veterinary teams may need to explain to curious pet parents. A new Veterinary Practice News article frames it as a fast-rising topic after CBD, with particular interest around inflammation, dermatology, and gastrointestinal disease, while also acknowledging that the current evidence base is limited and the marketplace hype is moving faster than the data. (veterinarypracticenews.com)
That timing matters. Over the past several years, cannabinoid discussion in veterinary medicine has centered mostly on CBD, especially in dogs, where the published literature is still modest but far more developed than it is for CBG. A 2024 comparative review of the endocannabinoid system and phytocannabinoids in veterinary species concluded that most veterinary cannabinoid studies still focus on CBD in dogs, and that only one published paper at that point had specifically evaluated physiological effects of CBG and CBGA in dogs. (link.springer.com)
The basic science case for CBG is what’s fueling interest. CBG is often described as a precursor cannabinoid in the cannabis plant, and reviews of the pharmacology literature suggest it may have anti-inflammatory, analgesic, neuroprotective, and metabolic effects. In the Veterinary Practice News piece, author Narda G. Robinson points to early signals that CBG may have stronger anti-inflammatory activity than CBD and may be especially appealing for topical use in skin disease. Supporting preclinical literature includes mouse-model work in atopic dermatitis and colitis, but those findings have not yet translated into robust clinical evidence in companion animals. (veterinarypracticenews.com)
The veterinary-specific data remain narrow. The 2022 Journal of Veterinary Pharmacology and Therapeutics study highlighted in later reviews evaluated oral CBG/CBGA-rich hemp extract in healthy dogs and found no adverse events during a two-week trial, with physical exams and clinicopathologic values staying within reference ranges. The same 2024 review noted no observed abnormalities in activity, neurologic status, or behavior, and no rise in liver enzymes in that short-term study. That’s useful reassurance, but it falls well short of proving efficacy for common clinical indications, and it doesn’t answer questions about chronic use, broader populations, or cats. (pubmed.ncbi.nlm.nih.gov)
Industry and expert commentary reflect that same tension between curiosity and caution. Veterinary Practice News presented CBG as a topic generating peer and client buzz, while broader review articles describe CBG as promising but still early-stage. Some veterinarian-authored industry education pieces are already discussing CBG in practical terms for canine calming or multimodal support, but those materials sit downstream of a still-limited evidence base and shouldn’t be confused with regulatory approval or established standard of care. (veterinarypracticenews.com)
Why it matters: For practicing veterinarians, the real story isn’t that CBG is ready for mainstream use. It’s that CBG is likely to become a more common part of client conversations, product marketing, and integrative treatment plans before the profession has strong answers on dosing, efficacy, adverse effects, formulation quality, or interactions with other therapies. That puts extra weight on informed consent, documentation, product scrutiny, and careful distinction between mechanistic promise, preclinical data, and actual clinical evidence. It also matters in a regulatory sense: FDA says it has not approved cannabis for treatment of any disease or condition, and it continues to treat therapeutic animal cannabis products as drugs subject to FDA requirements. (fda.gov)
FDA’s recent actions suggest the agency is still trying to map the veterinary cannabis landscape. In January 2025, FDA’s Center for Veterinary Medicine issued a request for information seeking input, especially from veterinarians, on use trends, quality standards, potential benefits, drug interactions, adverse events, safety problems, and toxicologic concerns tied to cannabis-derived products in animals. That request focused heavily on CBD and hemp-derived products, but it signals the broader context CBG will enter: growing market interest, incomplete evidence, and an unsettled oversight environment. (fda.gov)
What to watch: The next meaningful developments will be controlled clinical trials in dogs and cats, not just pharmacokinetic or rodent-model studies, along with clearer regulatory signals on veterinary cannabis-derived products and stronger expectations around labeling, quality control, and adverse-event reporting. (fda.gov)